The U.K. National Institute for Health and Care Excellence (NICE) gave radiation oncology firm Sirtex Medical positive guidance on the use of its selection internal radiation therapy (SIRT) with SIR-Spheres yttrium-90 microspheres for the treatment of adults with unresectable advanced hepatocellular carcinoma (HCC).
The NICE recommends SIR-Spheres in England and Wales as a fully funded and reimbursed option for adult patients with HCC if it's used in people with Child-Pugh grade A liver impairment when conventional transarterial therapies are inappropriate.
Also, the company must provide SIR-Spheres according to the commercial arrangement, the NICE said.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
